Glycomine Inc.
We are developing GLM101, a novel substrate replacement therapy for PMM2-CDG, a congenital disorder of glycosylation.
26 employees · est. 2013 · San Carlos, United States
Abliva AB is the older company (2000 vs 2013).
1 signal in the last 90 days
Side-by-Side Comparison
| Metric | Abliva AB | Glycomine Inc. |
|---|---|---|
| Founded | ||
| Founded | 2000 older | 2013 |
| Headquarters | ||
| Headquarters | Lund, Sweden | San Carlos, United States |
| Employees | ||
| Employees | 12 | 26 |
| Industry | ||
| Industry | Biotechnology, Health Care | Biotechnology, Health and Wellness, Pharmaceutical |
| Funding Stage | ||
| Funding Stage | Post Ipo Equity | Series C |
| Total Funding | ||
| Total Funding | $264.05M | $195.00M |
| Funding Rounds | ||
| Funding Rounds | 7 | 4 |
| Services | ||
| Services | Not tracked yet | Development of replacement therapies for rare genetic diseases, Clinical trial research and execution, Drug development for PMM2-CDG |
| Target Customers | ||
| Target Customers | Not tracked yet | Patients with PMM2-CDG, Caregivers and families of PMM2-CDG patients, Healthcare professionals specializing in genetic disorders |
| Taxonomy | ||
| Taxonomy | Mitochondrial Medicine, Mitochondrial Disorders, NAD⁺, NADH, Energy Replacement Therapy, Rare Diseases, Late-stage Development, Preclinical Development, Pharmaceuticals, Nasdaq Stockholm, Swedish Biotech Company | Substrate Replacement Therapy, PMM2-CDG, Congenital Disorder Of Glycosylation, Rare Disease, Metabolism, Protein Misfolding, Orphan Drugs, Therapeutic Options, Enzyme Therapy, Drug Development, Cellular Compartments, Medical Need |
| Website | ||
| Website | abliva.com | glycomine.com |
About Abliva AB
Abliva AB is a Swedish biotechnology company founded in 2000 with a mission to enhance mitochondrial health. Specializing in the development of medicines for mitochondrial diseases, Abliva focuses on addressing rare and severe conditions resulting from dysfunctional mitochondria, the cell's energy s...
About Glycomine Inc.
Glycomine Inc., founded in 2013 and headquartered in the United States, is a biotechnology pioneer developing breakthrough orphan drugs for serious, rare metabolic disorders and protein misfolding. Their unique approach involves using replacement therapies to target specific cellular compartments, a...
Be first to know when either one moves
Funding rounds, hiring surges, leadership changes and stack switches at Abliva AB and Glycomine Inc. — tracked continuously, sent the day they land.
Funding, hiring, leadership and stack changes at Abliva AB and Glycomine Inc. — by email.
Frequently Asked Questions
Compare Abliva AB with someone else
Start typing a company name or domain.